QuidelOrtho Corporation
$8.32-$0.60 (-6.7%)
Last close · Data as of Nov 20, 2026
- Market cap
- $1.0B
- P/E
- -0.9x
- EV / EBITDA
- -7.7x
- Revenue
- $2.7B
- Net margin
- -41.5%
- ROCE
- 1.1%
Price chart
Technical chartScreen technicals →-61.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -41.4%
- 3M
- -44.0%
- 6M
- -30.1%
- 1Y
- -61.0%
- 5Y
- -94.5%
52-week range
Day change -$0.60 (-6.7%) from $9 to $8 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in QDEL, bought on each weekday since 2021.
News & filings
What QuidelOrtho filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 1.1 billion US dollars in fiscal 2025.
Strengths
No strength stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.
Read moreShow less
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Shares outstanding
- 67.9M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $1.0B
- P/E
- -0.9x
- P/B
- 0.5x
- EV / EBITDA
- -7.7x
- EV / Sales
- 1.4x
- P/S
- 0.4x
- 52-week high
- $35.38
- 52-week low
- $8.32
Profitability
- Operating margin
- 2.0%
- Net margin
- -41.5%
- EBITDA margin
- -17.7%
- ROE
- -58.9%
- ROCE
- 1.1%
- ROA
- -19.6%
- Asset turnover
- 0.47
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $2.7B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -1.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -5.8%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -44.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$83.0M
Solvency
- Current ratio
- 1.50
- Debt / Equity
- 1.48
- Debt / Assets
- 0.49
- CFO / Net profit
- -0.09
- Cash / Market cap
- 16.3%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $2.7B |
| Cost of revenue | $1.5B |
| Gross profit | $1.3B |
| Operating expenses | $1.2B |
| Research and development | $186.2M |
| Selling, general and administrative | $746.3M |
| Operating income | $54.8M |
| Interest and other | -$1.2B |
| Pretax income | -$1.1B |
| Tax and other | $24.1M |
| Net income | -$1.1B |
Revenue and net profit
Revenue fell 1.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $3.3B | $548.7M |
| FY2023 | $3.0B | -$10.1M |
| FY2024 | $2.8B | -$2.1B |
| FY2025 | $2.7B | -$1.1B |
Cash flows
FY2025: $105.2M from operations, -$83.0M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $885.3M | $744.4M |
| FY2023 | $280.2M | $70.9M |
| FY2024 | $83.0M | -$112.1M |
| FY2025 | $105.2M | -$83.0M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $2.7B-1.9%1Y
- EBITDA
- -$482.6M
- Net profit
- -$1.1B
- Cash from operations
- $105.2M+26.7%1Y
- Free cash flow
- -$83.0M
- Revenue CAGR, 3Y
- -5.8%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $2.7B | -$482.6M | -$1.1B | -$83.0M | -58.9% | -1.9% | -44.8% |
Monthly returns
Month-by-month returns of QDEL across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $5.8B |
| Current assets | $1.4B |
| Non-current assets | $4.3B |
| Liabilities | $3.8B |
| Current liabilities | $966.1M |
| Non-current liabilities | $2.9B |
| Equity | $1.9B |
| Paid-in capital | $2.9B |
| Retained earnings | -$996.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; QDEL highlighted.
P/E against peers
QDEL has no positive P/E; the peer median is 19.7x.
Not shown (no positive earnings and no EV / Sales): QuidelOrtho Corporation, Omada Health, Inc., Azenta, Inc., EyePoint, Inc.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| QuidelOrtho CorporationQDELthis company | $1.0B | -0.9x | 0.5x | -58.9% | -7.7x |
| Omada Health, Inc.OMDA | $1.1B | -84.7x | 4.7x | -5.6% | -181.0x |
| Xeris Biopharma Holdings, Inc.XERS | $1.1B | 1916.5x | 77.6x | 4.0% | 28.6x |
| Collegium Pharmaceutical, Inc.COLL | $1.1B | 16.9x | 3.5x | 20.8% | 4.1x |
| CONMED CorporationCNMD | $1.1B | 22.5x | 1.0x | 4.6% | 10.5x |
| Azenta, Inc.AZTA | $1.1B | -18.9x | 0.6x | -3.2% | 20.8x |
| The Pennant Group, Inc.PNTG | $1.0B | 35.4x | 3.1x | 8.9% | 24.4x |
| EyePoint, Inc.EYPT | $1.0B | -4.4x | 3.4x | -75.8% | -4.1x |
| Artivion, Inc.AORT | $1.0B | 103.7x | 2.3x | 2.2% | 18.9x |
| Peer median | — | 19.7x | 3.3x | 3.1% | 14.7x |
Year-to-date ROI
QDEL since 1 January, against earlier years.
Historical volatility
QDEL's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 30.1% |
| FY2023 | 8.6% |
| FY2024 | 1.6% |
| FY2025 | 2.0% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $2.7B |
| Cost of revenueCost Of Revenue | $1.5B |
| Gross profitGross Profit | $1.3B |
| Operating expensesOperating Expense | $1.2B |
| Research and developmentResearch And Development | $186.2M |
| Selling, general and administrativeSelling General And Administration | $746.3M |
| Other operating expensesOther Operating Expenses | $97.7M |
| Depreciation and amortisationDepreciation And Amortization In Income Statement | $189.2M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement | $189.2M |
| Amortization | $189.2M |
| Amortisation of intangiblesAmortization Of Intangibles Income Statement | $189.2M |
| Total expensesTotal Expenses | $2.7B |
| Operating incomeOperating Income | $54.8M |
| Interest and other | |
| Pretax incomePretax Income | -$1.1B |
| TaxTax Provision | $24.1M |
| Net incomeNet Income | -$1.1B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $5.8B |
| Current assetsCurrent Assets | $1.4B |
| Non-current assetsTotal Non Current Assets | $4.3B |
| LiabilitiesTotal Liabilities Net Minority Interest | $3.8B |
| Current liabilitiesCurrent Liabilities | $966.1M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $2.9B |
| EquityTotal Equity Gross Minority Interest | $1.9B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $105.2M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $105.2M |
| Net income, continuing operationsNet Income From Continuing Operations | -$1.1B |
| Depreciation and amortisationDepreciation And Amortization | $442.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $442.0M |
| Depreciation | — |
| Stock-based compensationStock Based Compensation | $45.9M |
| Deferred taxDeferred Tax | $6.3M |
| Deferred income taxDeferred Income Tax | $6.3M |
| Operating gains and lossesOperating Gains Losses | $5.1M |
| Asset impairmentAsset Impairment Charge | $862.6M |
| Change in working capitalChange In Working Capital | -$125.8M |
| Other non-cash itemsOther Non Cash Items | $900.0k |
| Interest paid (operating)Interest Paid Cfo | $0.00 |
| Investing cash flowInvesting Cash Flow | -$192.7M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$192.7M |
| Capital expenditureCapital Expenditure | -$188.2M |
| Purchase of PP&EPurchase Of PPE | -$188.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$188.2M |
| AcquisitionsPurchase Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | — |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Other investing changesNet Other Investing Changes | -$4.5M |
| Financing cash flowFinancing Cash Flow | $155.8M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $155.8M |
| Debt issuedIssuance Of Debt | $2.6B |
| Debt repaidRepayment Of Debt | -$2.4B |
| Net debt issuedNet Issuance Payments Of Debt | $155.1M |
| Net short-term debt issuedNet Short Term Debt Issuance | $3.0M |
| Long-term debt issuedLong Term Debt Issuance | $2.6B |
| Long-term debt repaidLong Term Debt Payments | -$2.4B |
| Net long-term debt issuedNet Long Term Debt Issuance | $152.1M |
| Shares issuedIssuance Of Capital Stock | $6.1M |
| Common stock issuedCommon Stock Issuance | $6.1M |
| Net common stock issuedNet Common Stock Issuance | $6.1M |
| Common stock repurchasedCommon Stock Payments | $0.00 |
| Share buybacksRepurchase Of Capital Stock | $0.00 |
| Other financing chargesNet Other Financing Charges | -$5.4M |
| Change in cashChanges In Cash | $68.3M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 300.0% |
| Cash at the start of the yearBeginning Cash Position | $98.5M |
| Cash at the end of the yearEnd Cash Position | $169.8M |
| Free cash flowFree Cash Flow | -$83.0M |
| Supplemental |
Learn while you research
Academy chapters picked for QuidelOrtho Corporation and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read